Loading...
Market
Asciminib (Scemblix) market share over 30% in US by end of 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Market research reports and sales data from Novartis or third-party market analysis firms
Story
FDA Grants Accelerated Approval for Novartis's Asciminib (Scemblix) for CML, 25% Major Molecular Response Rate
Oct 29, 2024, 05:35 PM
The U.S. Food and Drug Administration (FDA) has granted accelerated approval for Novartis's asciminib (brand name Scemblix) as a treatment for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. Clinical trials demonstrated a 25% major molecular response rate at 24 weeks for asciminib, compared to 13% for the previous standard treatment, bosutinib. This approval positions asciminib as a promising option for frontline therapy in this patient population. Further application reviews are ongoing with other regulatory agencies, including Health Canada.
View original story
Similar markets
BridgeBio Pharma • 25%
Pfizer • 25%
Other • 25%
Tie • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Below 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
Above 60% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Yes • 50%
No • 50%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 20% • 25%
More than 20% • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Less than 20% • 25%
20%-40% • 25%
40%-60% • 25%
More than 60% • 25%
Less than 5% • 25%
5% - 10% • 25%
10% - 15% • 25%
More than 15% • 25%
Revuforj holds the largest market share • 25%
Revuforj holds the second largest market share • 25%
Revuforj holds the third largest market share • 25%
Revuforj holds less than third place in market share • 25%
Less than 10% • 25%
10% to 19% • 25%
20% to 29% • 25%
30% or more • 25%